Volcano Corporation  

(Public, NASDAQ:VOLC)   Watch this stock  
Find more results for VOLC
+0.14 (1.25%)
Nov 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.20 - 11.42
52 week 9.81 - 24.62
Open 11.20
Vol / Avg. 305,444.00/1.07M
Mkt cap 577.97M
P/E     -
Div/yield     -
EPS -0.74
Shares 51.60M
Beta 0.23
Inst. own 104%
Nov 20, 2014
Volcano Corp at Canaccord Genuity Medical Technologies & Diagnostics Forum
Nov 11, 2014
Volcano Corp at Credit Suisse Healthcare Conference
Nov 6, 2014
Q3 2014 Volcano Corp Earnings Call - Webcast
Nov 6, 2014
Q3 2014 Volcano Corp Earnings Release
Sep 9, 2014
Volcano Corp at Morgan Stanley Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -8.21% -8.76%
Operating margin -5.04% -7.60%
EBITD margin - 5.28%
Return on average assets -3.68% -3.98%
Return on average equity -10.48% -9.74%
Employees 1,800 -
CDP Score - -


United States - Map
+1-800-2284728 (Phone)
+1-858-7200325 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Volcano Corporation (Volcano) designs, develops, manufactures and commercializes a range of precision guided therapy tools, including intravascular ultrasound (IVUS), and fractional flow reserve (FFR), products. The Company is facilitating the adoption of functional percutaneous interventional (PCI), in which its FFR technology is used to determine whether or not a stent is necessary, and IVUS is used to guide stent placement and optimization. It markets its products to physicians and technicians who perform PCI procedures in hospitals and to other personnel who make purchasing decisions on behalf of hospitals. Its products consist of multi-modality consoles, which are marketed as stand-alone units or as customized units that can be integrated into a range of hospital-based interventional surgical suites called catheterization laboratories (cath labs). In June 2014, Volcano Corp acquired the entire share capital of AtheroMed Inc.

Officers and directors

Ronald A. Matricaria Chairman of the Board, Lead Independent Director
Bio & Compensation  - Reuters
R. Scott Huennekens President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
John T. Dahldorf Chief Financial Officer
Age: 57
Bio & Compensation  - Reuters
Michele Perrino President, Europe, Africa, Middle East, and India Operations
Age: 43
Bio & Compensation  - Reuters
Darin M. Lippoldt Executive Vice President, Chief Compliance Officer, General Counsel, Secretary
Age: 48
Bio & Compensation  - Reuters
John Onopchenko Executive Vice President - Strategy, Business Development and Integrations
Age: 55
Bio & Compensation  - Reuters
Daniel J. Wolterman Director
Age: 57
Bio & Compensation  - Reuters
Kieran T. Gallahue Independent Director
Age: 51
Bio & Compensation  - Reuters
Lesley H. Howe Independent Director
Age: 69
Bio & Compensation  - Reuters
Siddhartha Kadia Ph.D. Independent Director
Age: 44
Bio & Compensation  - Reuters